Breast cancer recurring less often after treatment

cp418

http://www.dispatch.com/content/stories/national_world/2014/11/26/breast-cancer-returning-less-after-treatment.html

 

wallycat

Did I miss something obvious?

So if you have a "mundane" er/pr positive cancer, nothing has changed except hopefully catching it sooner.

It did not speak to grade or type (IDC vs. ILC vs. Inflammatory vs. ?) in terms of less incidence of recurrence.

cp418

I missed it too.  This news article keeps coming up and repeating the same general statements.  Not sure how they came to these conclusions....

leggo

I think this info just keeps getting regurgitated because of where that particular researcher's interest lies. I can't imagine a world where we start chemo-prevention to deal with bc. 

http://www.bcam.qc.ca/content/doctors-debate-prevention-vs-cure

Kathy044

Thanks for posting this CP418. First full disclosure, I was treated at the BC Cancer Agency, though not at the same centre where Dr. Karen Gelmon is working (Dr Gelmon is the MO for some women on BCO though). Also when I had surgery I signed the papers allowing my tumour to be added to the BCCA database for use in future research. For both reasons I have been quite interested in reading about any research coming out of the BC Cancer Agency over the five yrs since dx.

Here is a link to the journal abstract: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.2461 There is free patient access to the full article pdf for personal use if you fill in a form to register.

CP418 they actually tested the tumour samples of the older group for HER2 status. That is how they were able to come to the HER2 conclusions between the older and new groups. The ER+ and ER- status they already had in the database so could make a comparison. I agree though, some of the newstories were ridiculous and why all the pink ribbons?

Wallycat I am ILC and that was the first thing that interested me when I looked at the outcomes too. Though the study did use grade and stage as well as ER and HER2 status in matching the women in the two cohouts they didn't look at age or type (idc, ilc, other) in the matching process however they did list the numbers on the Patient Characteristics table.,In the contemporary group 91.8 % of the women were IDC, but only 7.7 % were ILC. Same old, same old in these studies.

Leggo not much mention of chemotherapy in this study, the discussion mentions hormone therapy as the likely reason for the contemporary drop in recurrence for ER+ over the two periods.

Kathy